History of Establishment

Goal

To explore the life phenomena of biomolecules at a multi-scale level

June 2015

Discussions on establishing the Biomedical Institute for
Convergence at SKKU (proposal) began

December 2015

Establishment of the Biomedical Institute for
Convergence at SKKU (proposal) was finalized

August 2016

The Biomedical Institute for Convergence at SKKU (BICS)
held an international symposium

September 2016

Establishment of the Biomedical Institute for Convergence at SKKU (BICS)
was approved (Director: Prof. Kacunori Kataoka)

February 2017

Establishment of the Research Institute for Biomolecule Control (RIBC)

under the Biomedical Institute for Convergence at SKKU (BICS)

March 2017

Establishment of state-of-the-art infrastructure
and research infrastructure plans finalized

Specialization Plan

Characterized as a specialized research institute for the development, efficacy, and molecular mechanism studies of biomolecules

Biomolecular control and multiscale BioPhenome information acquisition
Utilization/industrialization of biomolecules (Accelerating the Development of Biobetters and Innovative New Drugs)
Hompage: https://swb.skku.edu/ribc/index.do

The final goal

Establishing a spatio-temporal life-form technology (ST-Biophenomics) that can create high added value in the biopharmaceutical industry and transform the R&D paradigm

A step-by-step goal

Innovative Therapeutics

Innovative Therapeutics

Cell & Gene Therapy (Prof. Kwon, Daehyuk)